Illustration of translucent cells and protein clusters in cyan and amber

Biosimilar Patent Dance: Why FDA Approval Does Not Mean Launch

Table of Contents

Why a biosimilar can win FDA approval years before launch: the BPCIA patent dance, 12 year exclusivity, settlements and what Biocon’s Pebrilzo deal shows.

Last updated: November 16, 2026

A biosimilar can win FDA approval years before it reaches pharmacies because approval and launch run on separate tracks. The BPCIA sets a 12 year exclusivity clock, a patent information exchange known as the patent dance, and a 180 day launch notice, and most launch dates end up set by settlement.

Scope: how US biosimilar approval, exclusivity, patent litigation and launch timing fit together, with the statutory deadlines from 42 U.S.C. 262 and recent settlements as worked examples.

Why can a biosimilar be approved but not launched?

FDA approval answers one question: is the product highly similar to its reference biologic with no clinically meaningful differences. It says nothing about patents. A biosimilar sponsor can hold an approved license and still be blocked from selling by the reference sponsor’s patents, a court injunction or, most often, a settlement that sets a licensed entry date.

Biocon’s pertuzumab biosimilar is the live example. Biocon said on November 16, 2026 that the FDA approved Pebrilzo (pertuzumab-qcay), a biosimilar to Genentech’s Perjeta, according to reports of its stock exchange filing. Under a settlement reached in October, its earliest licensed US launch is the third quarter of 2028. That is almost two years between approval and launch, by contract.

What is the BPCIA?

The Biologics Price Competition and Innovation Act created the abbreviated biosimilar pathway in section 351(k) of the Public Health Service Act, codified at 42 U.S.C. 262(k), plus the patent resolution procedures in 262(l). Original biologics are licensed under 351(a); biosimilars and interchangeables under 351(k). FDA’s Purple Book lists each licensed product with its BLA number and pathway.

The pathway is now well used. FDA’s biosimilar product information page, current as of October 28, 2026, lists approvals running from Zarxio in March 2015 to Lucamzi in October 2026.

How does 12 year biologic exclusivity work?

The statute sets two clocks from the date the reference product was first licensed. Under 262(k)(7), FDA cannot make a biosimilar approval effective until 12 years after first licensure, and a biosimilar application cannot even be submitted until 4 years after it. These clocks are independent of patents, which can run well past the 12 years.

Clock Statute Rule
Filing bar 262(k)(7)(B) No 351(k) application until 4 years after reference product first licensure
Reference exclusivity 262(k)(7)(A) Approval cannot be effective until 12 years after first licensure
First interchangeable exclusivity 262(k)(6) Ends at the earliest of 1 year after first commercial marketing; 18 months after a final court decision or dismissal; 42 months after approval if litigation is ongoing; or 18 months after approval if the applicant was not sued
Notice of commercial marketing 262(l)(8)(A) At least 180 days before first commercial marketing

Exclusivity exceptions exist in 262(k)(7)(C) for supplements and certain later applications by the same sponsor, which prevents a company from restarting the clock with minor changes.

What is the biosimilar patent dance?

The patent dance is the stepwise exchange of the biosimilar application and patent lists set out in 262(l). It is designed to narrow the patents in dispute before a lawsuit, and each step has a statutory deadline.

Step Statute Who acts Deadline
1. Share the application and manufacturing information 262(l)(2) Biosimilar applicant Within 20 days after FDA notifies the applicant that its application is accepted for review
2. List patents that could be asserted 262(l)(3)(A) Reference sponsor Within 60 days of receiving the application
3. Respond with noninfringement and invalidity positions 262(l)(3)(B) Applicant Within 60 days of receiving the list
4. Reply to the applicant’s positions 262(l)(3)(C) Reference sponsor Within 60 days of receiving the statement
5. Negotiate which patents to litigate 262(l)(4) Both If no agreement within 15 days, simultaneous list exchange under 262(l)(5)
6. File the first wave lawsuit 262(l)(6) Reference sponsor Within 30 days of agreement or of the list exchange
7. Give notice of commercial marketing 262(l)(8)(A) Applicant At least 180 days before launch; the sponsor may then seek a preliminary injunction

Add the steps up and the exchange alone can consume roughly eight months before the first lawsuit is filed. That is our arithmetic from the statutory deadlines, not a statutory total; actual timing depends on when each party acts.

Does an applicant have to do the patent dance?

In practice it is a strategic choice, and the statute attaches consequences to how each side participates. Under 262(l)(9), neither side may bring a declaratory judgment action on the listed patents before the 180 day notice of commercial marketing is received, and further rules in the same paragraph govern what happens when a party does not follow the steps. Applicants that participate get the fight narrowed and an early view of the patent estate; applicants that skip it accept a less predictable litigation path. This is an area where the case law matters, so treat the statute as the starting point and confirm a specific filing strategy with counsel.

Why do most biosimilar fights end in settlement?

Because both sides trade uncertainty for a date. A reference sponsor with dozens of patents can make litigation long and costly, and a biosimilar sponsor without a date cannot plan manufacturing, contracting or launch inventory. A settlement gives the biosimilar a licensed entry date and gives the originator a predictable decline curve.

Recent examples show how far approval and launch can sit apart:

Biosimilar (sponsor) Reference product Litigation and settlement Licensed US entry
Pebrilzo, pertuzumab-qcay (Biocon Biologics) Perjeta (Genentech) Genentech sued July 29, 2026 on 28 patents in the District of New Jersey; dismissed without prejudice October 14, 2026 after a global settlement and license Earliest Q3 2028; EU and UK Q1 2027
Eydenzelt, CT-P42 (Celltrion) Eylea 2 mg (Regeneron) Settlement announced October 20, 2025; FDA approved Eydenzelt October 10, 2025 December 31, 2026

Settlement terms beyond the entry date are usually confidential, so the launch date is often the only number the market gets.

What does interchangeability add?

Interchangeability is a higher designation. FDA says an interchangeable product may be substituted at the pharmacy without consulting the prescriber, subject to state pharmacy law, and a manufacturer must specifically ask for it. The first interchangeable for a reference product earns its own exclusivity under 262(k)(6), which blocks FDA from finding a second product interchangeable for that period.

FDA’s review and approval page says manufacturers typically conduct a switching study to support interchangeability, and that for certain interchangeable biosimilars FDA evaluates information on the effects of switching. Expectations here have been under review, so check FDA’s current interchangeability guidance on fda.gov before planning a program around it.

Checklist: how to model a biosimilar launch date (our framework)

  1. Find the reference product’s first licensure date and add 12 years for the earliest effective approval.
  2. Pull the reference sponsor’s patent estate and note expiry dates past the 12 year mark.
  3. Check whether the applicant entered the patent dance and whether an (l)(6) lawsuit was filed, and when.
  4. Look for a settlement and a licensed entry date; that usually replaces patent expiry as the real date.
  5. Track the 180 day notice of commercial marketing; launch cannot come sooner.
  6. For interchangeables, map 262(k)(6) first exclusivity windows for competitors.
  7. Check ex US dates; settlements often stagger Europe ahead of the US, as Biocon’s Q1 2027 EU and UK dates do.
  8. Recheck FDA’s biosimilar list and Purple Book for new approvals that change the competitive count.

What to watch next

  • Celltrion’s licensed Eylea biosimilar entry date of December 31, 2026.
  • Biocon’s Pebrilzo EU and UK launches from Q1 2027, ahead of the US date.
  • FDA’s guidance on interchangeability and switching studies.
  • New BPCIA filings against biologics approaching their 12 year mark.

FAQ

What is the BPCIA patent dance?

It is the exchange of a biosimilar application and patent lists between the biosimilar applicant and the reference product sponsor under 42 U.S.C. 262(l), with set deadlines, before patent litigation begins.

How long is biologic exclusivity in the US?

Twelve years from the reference product’s first licensure before a biosimilar approval can take effect, with a 4 year bar on even filing a biosimilar application.

Why are biosimilars approved but not launched?

FDA approval does not resolve patents. Patent litigation, injunctions or settlement entry dates often hold launch back for months or years after approval.

What is the 180 day notice of commercial marketing?

Under 262(l)(8)(A), a biosimilar applicant must notify the reference sponsor at least 180 days before first commercial marketing, which opens a window for the sponsor to seek a preliminary injunction.

Do biosimilar applicants have to do the patent dance?

It is a strategic choice. How each side participates changes the litigation options available under 262(l)(9), so applicants weigh it carefully with counsel.

When can Biocon launch its Perjeta biosimilar in the US?

Biocon’s earliest licensed US launch date for Pebrilzo is the third quarter of 2028, under its settlement with Genentech.

What is an interchangeable biosimilar?

A biosimilar that FDA has found can be substituted at the pharmacy without consulting the prescriber, subject to state law. Sponsors must apply specifically for the designation.

How long does first interchangeable exclusivity last?

Until the earliest of 1 year after first commercial marketing, 18 months after a final court decision or dismissal, 42 months after approval if litigation is ongoing, or 18 months after approval if the applicant was not sued.

Where can I check whether a biosimilar is approved?

FDA’s biosimilar product information page and the Purple Book database, which lists licensed biologics and their 351(a) or 351(k) pathway.

Do settlements always delay launch?

They set a date, which can be earlier than patent expiry would allow. The trade is certainty for both sides, and the date is often the only term disclosed.

Sources

  • 42 U.S.C. 262, Regulation of biological products, U.S. Code via govinfo.gov (primary).
  • FDA, Biosimilar Product Information, content current as of October 28, 2026 (primary).
  • FDA, Biosimilars Basics for Patients and Review and Approval pages (primary).
  • FDA, Purple Book database (primary).
  • Goodwin, Big Molecule Watch, “Genentech and Biocon settle pertuzumab biosimilar BPCIA litigation,” October 20, 2026 (attributed: case filing date, patent count, dismissal date, launch dates per Biocon).
  • Pearce IP, Celltrion Eydenzelt settlement report, October 20, 2025 (attributed: approval and launch dates).
  • CASRAI report on Biocon’s November 16, 2026 exchange filing on the Pebrilzo approval (attributed).

Related coverage

Get the daily briefing: subscribe to BioMed Nexus.

Featured Articles

Join 65,000+ Biotech, MedTech, and Pharma Leaders

Your Daily Edge in Biotech, MedTech, and Pharma

Get trusted, high-signal updates every morning
Breakthroughs, trial data, deals, and the news that matters